AI assistant
Summit Therapeutics Inc. — Director's Dealing 2022
Jan 5, 2022
30436_dirs_2022-01-05_0816000d-4187-49ef-a837-2393c2287c20.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-01-03
Reporting Person: Mahatme Ujwala (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-03 | Stock Option (right to buy) | $2.82 | A | 25000 | Acquired | 2032-01-03 | Common Stock (25000.0) | Direct |
| 2022-01-03 | Stock Option (right to buy) | $2.82 | A | 47872 | Acquired | 2032-01-03 | Common Stock (47872.0) | Direct |
Footnotes
F1: The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022.
F2: Not applicable.
F3: The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022.
F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $54,000.